Kornimate/medical-research-clean huggingface dataset:
comparison of thoracic epidural pressure in the prone and lateral decubitus position

Conditions: Thoracic Epidural Injection

Summary: it is reported that the distribution of contrast medium had an obvious correlation with the extent of sensory analgesia after injection of la. our previous study showed that different posture (prone vs. lateral decubitus) resulted in different degree of contrast medium spread. we supposed that differences of epidural pressure between diverse postures might be one factor contributing those differences of epidurography. this study was designed to compare the epidural pressure and extent of spread of epidurography between prone and lateral decubitus position

it is known that postoperative pain after thoracotomy or lobectomy is very severe, therefore, intraoperative or postoperative pain management using continuous thoracic epidural catheterization is suggested good option to prevent this potential complication. the spread of local anesthetics is influenced by various factors including volume, location of needle insertion, speed of injection, patient position, age, weight and height. however, there are few studies about the effect of different patient position affeting the epidural pressure and the extent of spread of contrast medium during thoracic epidural catheterization. studies of lumbar epidural blockade have shown that lateral position can produce 0-3 segment more to the dependent position compared to the supine position. when the same amount of local anesthetic was injected in supine of sitting position, the most cephalad level of spread was indifferent. recent studies showed that neck flexion demonstrated significant cephalad spread of contrast dye in high thoracic epidural blockade. the purpose of this study was to compare and evaluate the changes of epidural pressure with extent of spread of contrast medium between different posture

Eligibility criteria:
inclusion criteria: * lung cancer * liver cancer * stomach cancer * pancreas cancer exclusion criteria: * coagulopathy * infection * previous spine fusion at thoracic level

Keywords: epidurography epidural pressure patient posture
evaluation of a hysteroscopic method with vaporization in the hysteroscopic treatment of submucosal uterine fibroids

Conditions: Uterine Fibroids

Summary: operative hysteroscopy (oh) is an endoscopic technique for the treatment of benign intrauterine lesions and in particular uterine fibroids. the limit of this technique is the duration of the operation which is correlated with the operative risks. thus, when there is a large fibroid or several fibroids, this technique can sometimes not be used or require several sessions. today there is a new technique of ho that theoretically allows a gain in operative time. there are few comparative studies showing a clinically interesting gain in operating time. the aim of this study is to compare the operative time between the classical ho technique by resection and the vaporization technique. this is a randomized, single-center study. the study population corresponded to women aged over 18 years requiring operative hysteroscopy for fibroids. after obtaining informed consent, patients will be randomized into two groups: a vaporization hysteroscopy group and a resection hysteroscopy group. the primary endpoint will be operative time. the secondary endpoints will be intraoperative characteristics and complications (amount of distension fluid used, cervical injury, uterine perforation), immediate postoperative data (pain) and medium-term data (postoperative synechiae). the starting hypothesis is that the technique of hysteroscopy by vaporization would reduce the operative time by 30%. the number of subjects required per group will be 27 patients, or 54 patients in total over 24 months. the expected results are a significant decrease in operative time with the vaporization hysteroscopy technique. this would be important because the reduction in operative time is associated with a reduction in complications of operative hysteroscopy and the possibility of treating larger fibroids with this technique.


Eligibility criteria:
inclusion criteria: * patient at least 18 years old. * non-pregnant patient * a patient who had an ultrasound confirming the presence of a uterine fibroid to be treated less than 6 cm. * patient who had a diagnostic hysteroscopy confirming the presence of a uterine fibroid to be treated of type 0, 1 or 2 according to the figo classification. * patient presenting an indication for intra uterine fibroid resection (bleeding, fertility problems) by operative hysteroscopy. * patient having agreed to participate in the study and having signed an informed consent. exclusion criteria: * minor patient * patient not affiliated to a social security system * persons benefiting from special protection: by virtue of articles l1121-5 to l1121-8 of the public health code: pregnant or breast-feeding women, minors, adults under guardianship or curatorship, persons deprived of liberty. * patient refusing to sign the consent or unable to receive the information necessary to give informed consent.
organic pollutants in pelvic endometriosis

Conditions: Endometriosis; Infertility Unexplained

Summary: the health toxicity of polycyclic aromatic hydrocarbons (pahs), present in air and food, generated during energy production and waste incineration, is well known. pahs can activate the aryl hydrocarbon receptor, which may interact with classic estrogen receptors and modify estrogen-dependent inflammation in endometriosis. there is no data on the hypothetical role of pahs in the etiopathogenesis of endometriosis. the aim was to compare pahs concentrations in visceral fat in women with endometriosis and idiopathic infertility.

a prospective cohort tertiary-center study includes women undergoing laparoscopy due to pelvic endometriosis (arm 1) or/and idiopathic infertility (arm 2). a sample of 1 ml of the greater omentum is collected intraoperatively for detection of 16 pahs, i.e. acenaphthene, acenaphthylene, anthracene, fluoranthene, fluorene, naphthalene, phenanthrene, pyrene, benz\[a\]anthracene, benzo\[b\]fluoranthene, benzo\[k\]fluoranthene, benzo\[ghi\]perylene, benzo\[a\]pyrene, chrysene, dibenz\[a,h\]anthracene, and indeno\[1,2,3-cd\]pyrene, by gas chromatography-isotope dilution mass spectrometry method. the concentration of selected pahs in visceral fat in both populations will be compared. the correlation of concentrations of selected pahs with the occurrence of infertility, pelvic pain syndrome, intensity of pain, peritoneal adhesions and the degree of endometriosis will be checked.

Eligibility criteria:
inclusion criteria: i) age 18-45, ii) indications for surgical treatment of endometriosis, iii) indications for invasive diagnostics and surgical treatment of idiopathic infertility. exclusion criteria: -

Keywords: endometriosis, unexplained infertility, polycyclic aromatic hydrocarbons
short course radiation therapy in palliative treatment of thoracic cancer

Conditions: Thoracic Cancer; Radiotherapy; Palliative Care

Summary: aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic thoracic malignant lesions

standard treatment for thoracic lesions (3000 cgy in 10 daily fractions of 300 cgy each) is compared with experimental treatment (2000 cgy in 4 fractions of 500 cgy twice a day) to demonstrate non-inferiority of this scheme

Eligibility criteria:
inclusion criteria: * symptomatic thoracic malignant lesions (primary solid tumors or metastases from solid tumor) * age\> 18 years * eastern cooperative oncology group (ecog) performance status 0-3 * no changes in supportive care in the week before radiotherapy exclusion criteria: * pregnancy * previous irradiation of the same region

Keywords: short course radiotherapy symptomatic thoracic lesions
ckd-337 drug interaction study

Conditions: Dyslipidemia (Fredrickson Type Ⅱa); Dyslipidemia (Fredrickson Type Ⅱb)

Summary: the purpose of this study is to evaluate a pharmacokinetic drug interaction between atorvastatin and fenofibrate in healthy subjects.


Eligibility criteria:
inclusion criteria: * a healthy male volunteer between 19 and 55 years old. * bmi between 18.5 and 27. * able to participate in the entire trial * signed the informed consent form prior to study participation. exclusion criteria: * clinically significant digestive system, cardiovascular system, respiratory system, endocrine system, hepatic system, renal system * sit sbp \< 100mmhg or sit sbp ≥ 150mmhg or sit dbp \< 70mmhg or sit dbp ≥ 100mmhg * have acute infection history within 14 days * have a allergic disease of need to treat * have hypersensitivity reactions history for ip or any specific drugs. * ast, alt or total bilirubin \> unl \* 1.5 * estimated gfr \< 60 ml/min * genetic problems such as galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption * a heavy smoker (cigarette \> 10 cigarettes per day) * a heavy alcohol consumer (alcohol \> 140g/week) * a heavy grapefruit consumer (more than 1cup per a day) * have a history of drug abuse or showed a positive for urine drug test. * administrated ip within 60 days prior to screening * rhabdomyolysis include of having a history or family history of genetic muscle diseases * positive for hiv antibody, hbsag, hcv antibody test * previously donate whole blood within 60 days or component blood within 30 days * subject takes ethical drug or herbal medicine within 30 days * clinically significant laboratory test result * an impossible one who participates in clinical trial by investigator's decision including other reason
efficacy of levetiracetam in control of neonatal seizures guided by an eeg

Conditions: Neonatal Seizures

Summary: over the last three decades, several tools have been developed to enhance the detection and treatment of neonatal seizures. regarding treatment, phenobarbital maintains is still used as a first-line therapy worldwide. however, newer anti-epileptic drugs (aed) s such as, levetiracetam, bumetanide, and topiramate are increasingly being applied to the neonatal population, offering the potential for seizure treatment with a significantly better side-effect profile. levetiracetam is a very promising medication for the treatment of neonatal seizures. it has been in clinical use for almost a decade in adults and older children with good efficacy, an excellent safety profile and near ideal pharmacokinetic characteristics. it has been approved and used for treatment of seizures in infants starting one month of age since 2012. the investigators are comparing the efficacy of levetiracetam to that of phenobarbital as a first-line drug in control of neonatal seizures. the investigators monitor the efficacy through assessment of frequency of seizures before and after drug administration, amplitude integrated eeg changes in background activity and seizure frequency in participants, duration taken for participants to be seizure free and short term neurodevelopmental outcome and eeg at 3 months of age


Eligibility criteria:
inclusion criteria: * all full term neonates experiencing seizures due to; post-hypoxic or post-ischemic encephalopathy, intracerebral hemorrhage, cerebral infection, inborn errors of metabolism or malformations of cortical development exclusion criteria: * preterm neonates * full term neonates with seizures due to metabolic derangements (hypoglycemia, hypocalcemia or hypomagnesemia) * full term neonates with impaired renal functions.

Keywords: eeg with periodic abnormalities levetiracetam phenobarbitone neonatal seizures neurodevelopmental abnormality
a novel method of lung isolation compared with standard methods in a model of massive pulmonary hemorrhage

Conditions: Pulmonary Hemorrhage

Summary: dr. purdy has developed a novel bronchial blocker device that has multiple applications. in this project, a simulation model of massive pulmonary hemorrhage in an adolescent intubating manikin will be used to compare the novel method against 3 published methods of lung isolation.

purpose: to compare a novel airway device in a realistic adolescent airway model of massive pulmonary hemorrhage to three standard methods of lung isolation. hypothesis: the novel method will be as fast or faster than traditional methods. justification: lung isolation in massive pulmonary hemorrhage is associated with mortality rates as high as 40%. current methods of lung isolation are challenging and have a number of limitations. the development of this novel device was a response to the limitations of current solutions and could significantly increase the speed and ease of placing a bronchial blocker under these circumstances. objectives: (1) to determine the length of time required for successful lung isolation in each of the four methods trialed. (2) to determine the length of time required for intubation in each of the four methods trialed. (3) to describe challenges in each method within the scenario of massive pulmonary hemorrhage. (4) to assess the utility of the model of massive pulmonary hemorrhage in future simulations. research design: we propose a within-subject randomized procedure evaluation study comparing the placement of a novel bronchial blocker with three standard methods of lung isolation in a massive pulmonary hemorrhage simulation. analysis: mixed effects model will be used to test the difference in total time to lung isolation between the novel method and the other three methods, with the subject as the random variable. if normality and homogeneity assumptions of the mixed-effects model are not fulfilled, then the non-parametric wilcoxon signed-rank test would be used to compare the novel method to each of the other methods. time constraints are placed on completion of a task, as such, we will complete sensitivity analysis where we include all participants in the analysis compared to excluding those that were unable to complete at least 1 method.

Eligibility criteria:
inclusion criteria: * practicing anesthesiologists * anesthesia fellows exclusion criteria: * those who don't want to participate

Keywords: simulation anesthesia
cigarette smoking in non-alcoholic steatohepatitis

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: this non-randomized clinical trial was performed to clarify the effect of cigarette smoking reduction on liver function and some anthropocentric indices in smoker patients with non-alcoholic steatohepatitis.

after excluding other causes of high aminotransferase level, participants with persistent elevated serum aminotransferase levels and evidence of fatty liver in ultrasonography were presumed to have non-alcoholic steatohepatitis. those with nafld liver fat score greater than (-0.64) were enrolled. they were assigned to lifestyle modification alone or lifestyle modification plus smoking reduction groups. liver fat content, fasting serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and low-density lipoprotein, homeostasis model assessment-insulin resistance(homa-ir), and anthropometric measurements (body mass index and waist circumference) were checked at baseline and six months later.

Eligibility criteria:
inclusion criteria: smokers with persistent elevated aminotransferase levels with the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic. exclusion criteria: * alcohol use (more than 20 gram per day in men and 10 gram per day in women per day), * heart disease (ischemic or congestive), * hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion), * renal disease (serum creatinine concentration of \> 1.5 mg/dl), * any severe systemic co-morbidities, neoplasm, * using any hepatotoxic medication during the past 3 months, * pregnant or lactating women.

Keywords: steatohepatitis smoking aminotransferase
patients with chronic pelvic pain with vaginal microbiota

Conditions: Pelvic Pain

Summary: vaginal microorganisms play an important role in the occurrence and development of many diseases, such as persistent infection of high-risk human papillomavirus (hr-hpv) causing cervical intraepithelial neoplasia and cervical cancer, and the role of microorganisms in chronic prostatitis.


Eligibility criteria:
inclusion criteria: * those are aged 20 to 45 years old, have vaginal intercourse more than 3 years, and aren't in menstrual, pregnancy or puerperium period. exclusion criteria: * those are aged more than 45 years old without hpv infection in the last one year, having no vaginal intercourse, and those can't cooperate the examiner. women who are hiv or hepatitis b/c positive, have autoimmune disorders and systemic disease (like diabetes mellitus, hormone treatment diseases, severe liver and kidney dysfunction), or have severe mental illness and malignant tumors are also excluded. at the same time, all the participants should meet the following requirements: no vagina douching within last 2 days, no vaginal intercourse within last 3 days, no systemic application of antifungal agents or antibiotics or pessaries within last 14 days of sampling.
combined thc and cbd drops for treatment of crohn's disease

Conditions: Crohn's Disease

Summary: there are many reports about efficacy of cannabis in crohn's disease but no controlled trials. the aim of the proposed trial is to investigate the efficacy of oil containing the cannabinoids thc and cbd given by mouth for induction of remission in crohn's disease.

the investigators have recently published a retrospective observational study about the beneficial effect of cannabis in crohn's disease. the investigators have also concluded a double blind placebo controlled study of inhaled cannabis in the treatment of crohn's disease. both studies have shown significant symptomatic improvement of disease. however, objective parameters of inflammation were not measured. the question arises as to whether the observed improvement is merely symptomatic or due to a real change in inflammation. in addition, administration per os is a healthier option than smoking but the efficacy of oral cannabis was not investigated. the aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's disease patients compared to placebo. treatment success will be defined as a decrease of at least 100 points in cdai after 8 weeks of treatment. secondary aims: 1. remission of disease i.e cdai of less the 150 points. 2. improvement of at least one point in endoscopic disease activity index 3. improvement of crp and calprotectine 4. improvement of blood cytokine levels 5. improvement of at least 30 points in quality of life as measured by the sf 36. in addition the investigators will monitor side effects by questionnaires addressed to the patients and to a significant relative of the patients.

Eligibility criteria:
inclusion criteria: 1. patients with a diagnosis of crohn's disease of at least 3 months duration, which was proved by either endoscopy or appropriate imaging study. 2. patients who have failed treatment with either 5 asa or corticosteroids or immunomodulators or biologic agents, or steroid dependant patients, or patients who were treated by the above mentioned drugs and could not tolerate them due to side effects. 3. age 20 or older. 4. able to sign informed concent 5. active crohn's disease with a cdai 200 or more. - exclusion criteria: 1. patients with a diagnosis of a mental disorder 2. patients who by the judgment of their physician are likely to develop drug addiction. 3. pregnant women or women who are intending to become pregnant 4. patients with a known cannabis allergy 5. patients who are not capable of giving an informed consent 6. patients with an impending operation due to crohn's disease. -

Keywords: crohn's disease ibd cannabis thc cbd
activity based locomotor exercise program-wait-list controlled research

Conditions: Spinal Cord Injuries

Summary: at courage kenny rehabilitation institute, rehabilitation for individuals with spinal cord injury (sci) is being led by the nih funded neurorecovery network (nrn) community fitness and wellness program through the activity-based locomotor exercise program (able). any individual with a spinal cord injury who is eligible for the able program is eligible for participation in the neurorecovery network research project (nrn). the purpose of the able power study is to evaluate the effectiveness of activity-based locomotor exercise programs in individuals with sci through a wait-list controlled design. individuals who have a spinal cord injury and are on the wait list for able will be enrolled in this project for a year while they wait for an opening in the able program. changes that occur while participants are on the wait list will be compared to changes that occur after they are enrolled in able. a difference in the rate of improvement after enrollment in the intervention would be attributed to the able intervention. individuals participating in the able program will receive the able intervention regardless of participation in the able power research study. in this design, there will be two measures in the year prior to enrollment in able, and two measures in the year after enrollment, and the two time periods would be compared to the data collected at enrollment into able.


Eligibility criteria:
inclusion criteria: * the participant must be eligible for the neurorecovery network (nrn) study. eligibility criteria for the nrn study are as follows: the participant must have a spinal cord injury, at any spinal level or time since injury. individuals with uncontrolled diabetes, uncontrolled seizures, uncontrolled autonomic dysreflexia, uncontrolled hypotension, unstable angina, history of heart attack, osteoporosis, or weight of more than 275 pounds (due to the weight limit of the partial weight supported treadmill system) are not eligible. * the participant must be on the able wait list. exclusion criteria: • the participant must not have previously participated in able.
sophia step study - a behaviour change program on physical activity in persons with pre- and type 2 diabetes

Conditions: Type 2 Diabetes; Prediabetes

Summary: the aim of the study is to investigate the effects of two levels of primary care physical activity interventions on metabolic control and cardiovascular risk factors, compared to usual care in patients with pre- and type 2 diabetes. the hypothesis is that both levels of interventions have effect on hba1c with the more intense group intervention having superior effects.

regularly physical activity may decrease the risk for type 2 diabetes, cardiovascular diseases, overweight and premature deaths. despite the evidence that physical activity is beneficial to health,it is often ignored and underused aspect in diabetes care. the aim of the study is to investigate the effects of two levels of primary care physical activity interventions on metabolic control and cardiovascular risk factors, compared to usual care in patients with pre- and type 2 diabetes.

Eligibility criteria:
inclusion criteria: ability to communicate in swedish age 40-80 years type 2 diabetes: diagnosed type 2 diabetes with a duration of \>=1 year pre-diabetes: hba1c \>39-\ 5.6 mmol/l exclusion criteria: * myocardial infarction in the past 6 months * serum creatinine \>140 * diabetic ulcer or risk for ulcer * prescribed insulin in past 6 months * additional disease prohibiting physical activity * have experienced repeated hypoglycaemia or severe hypoglycaemia in past 12 months * classified in very hard-intensity activity according to stanford brief activity survey * having no access to internet.